

Supplemental Digital Content 3. Susceptibilities to oral and intravenous antimicrobial agents of *S. pneumoniae* isolates classified by resistance genotype^a (n = 108)

| Oral antimicrobial agent and resistance class | MIC (µg/mL) | | | Intravenous antimicrobial agent and resistance class | MIC (µg/mL) | | |
|---|-------------|-------------------|-------------------|--|-------------|-------------------|-------------------|
| | Range | MIC ₅₀ | MIC ₉₀ | | Range | MIC ₅₀ | MIC ₉₀ |
| Cefcapene | 0.016–8 | 0.5 | 1 | Cefotaxime | 0.008–2 | 0.25 | 0.5 |
| gPSSP | 0.016 | 0.016 | 0.016 | gPSSP | 0.008–0.016 | 0.008 | 0.016 |
| gPISP (<i>pbp2x</i>) | 0.125–1 | 0.25 | 0.5 | gPISP (<i>pbp2x</i>) | 0.063–0.25 | 0.125 | 0.25 |
| gPISP (<i>pbp1a+2x</i>) | 0.5–4 | 1 | 4 | gPISP (<i>pbp1a+2x</i>) | 0.125–1 | 0.5 | 1 |
| gPISP (<i>pbp2x+2b</i>) | 0.125–1 | 0.25 | 1 | gPISP (<i>pbp2x+2b</i>) | 0.063–0.25 | 0.25 | 0.25 |
| gPRSP (<i>pbp1a+2x+2b</i>) | 0.5–8 | 1 | 1 | gPRSP (<i>pbp1a+2x+2b</i>) | 0.25–2 | 0.25 | 0.5 |
| Cefditoren | 0.016–2 | 0.125 | 0.5 | Ceftriaxone | 0.008–1 | 0.125 | 0.5 |
| gPSSP | 0.016 | 0.016 | 0.016 | gPSSP | 0.008–0.016 | 0.008 | 0.008 |
| gPISP (<i>pbp2x</i>) | 0.063–0.25 | 0.125 | 0.25 | gPISP (<i>pbp2x</i>) | 0.063–0.25 | 0.125 | 0.125 |
| gPISP (<i>pbp1a+2x</i>) | 0.125–1 | 0.5 | 1 | gPISP (<i>pbp1a+2x</i>) | 0.125–0.5 | 0.5 | 0.5 |
| gPISP (<i>pbp2x+2b</i>) | 0.125–0.25 | 0.25 | 0.25 | gPISP (<i>pbp2x+2b</i>) | 0.063–0.25 | 0.125 | 0.25 |
| gPRSP (<i>pbp1a+2x+2b</i>) | 0.125–2 | 0.5 | 0.5 | gPRSP (<i>pbp1a+2x+2b</i>) | 0.25–1 | 0.25 | 0.5 |
| Tebipenem | 0.001–0.125 | 0.004 | 0.125 | Tazobactam / Piperacillin | 0.031–4 | 0.5 | 4 |
| gPSSP | 0.001–0.004 | 0.002 | 0.002 | gPSSP | 0.031 | 0.031 | 0.031 |
| gPISP (<i>pbp2x</i>) | 0.002–0.004 | 0.004 | 0.004 | gPISP (<i>pbp2x</i>) | 0.063–0.5 | 0.25 | 0.5 |
| gPISP (<i>pbp1a+2x</i>) | 0.008–0.031 | 0.016 | 0.031 | gPISP (<i>pbp1a+2x</i>) | 0.25–1 | 0.5 | 1 |
| gPISP (<i>pbp2x+2b</i>) | 0.004–0.031 | 0.008 | 0.031 | gPISP (<i>pbp2x+2b</i>) | 0.5–1 | 1 | 1 |
| gPRSP (<i>pbp1a+2x+2b</i>) | 0.031–0.125 | 0.063 | 0.125 | gPRSP (<i>pbp1a+2x+2b</i>) | 1–4 | 4 | 4 |
| Tosufloxacin | 0.25–0.5 | 0.5 | 0.5 | Meropenem | 0.016–1 | 0.031 | 1 |
| gPSSP | 0.25–0.5 | 0.5 | 0.5 | gPSSP | 0.016–0.031 | 0.031 | 0.031 |
| gPISP (<i>pbp2x</i>) | 0.25–0.5 | 0.5 | 0.5 | gPISP (<i>pbp2x</i>) | 0.031–0.063 | 0.031 | 0.031 |
| gPISP (<i>pbp1a+2x</i>) | 0.25–0.5 | 0.5 | 0.5 | gPISP (<i>pbp1a+2x</i>) | 0.063–0.25 | 0.125 | 0.25 |
| gPISP (<i>pbp2x+2b</i>) | 0.25–0.5 | 0.25 | 0.5 | gPISP (<i>pbp2x+2b</i>) | 0.063–0.25 | 0.125 | 0.25 |
| gPRSP (<i>pbp1a+2x+2b</i>) | 0.25–0.5 | 0.5 | 0.5 | gPRSP (<i>pbp1a+2x+2b</i>) | 0.5–1 | 1 | 1 |

^a gPSSP indicates possession of 3 normal *pbp* genes, *pbp1a*, *pbp2b*, and *pbp2x*; gPISP (*pbp2x*) indicates 1 abnormal *pbp2x* gene; gPISP (*pbp1a+pbp2x*) indicates 2 abnormal genes, *pbp1a* and *pbp2x*; gPISP (*pbp2x+pbp2b*) indicates 2 abnormal genes, *pbp2x* and *pbp2b*; gPRSP (*pbp1a+pbp2x+pbp2b*) indicates 3 abnormal *pbp* genes. One strain gPISP (*pbp2b*) was omitted.